Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat QTc study in advanced solid tumors
NCT03330106Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pevonedistat in solid tumor (advanced stage) (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Fridericia-corrected QT Interval. Started Nov 2017; status: completed.
02
Drugs
pevonedistat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03330106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330106.